Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

This study is testing a combination of chemotherapy (gemcitabine), an anti-angiogenesis drug (endostar), and an immunotherapy drug (envafolimab) in elderly patients with locally advanced nasopharyngeal carcinoma (cancer of the upper throat/nasal passage area) who cannot tolerate standard intensive treatments. **You may be eligible if...** - You are 65 years or older - You have newly diagnosed nasopharyngeal cancer confirmed by biopsy - Your cancer is at clinical stage III–IVA - Your general health score (Karnofsky) is 60 or above - You have adequate organ function **You may NOT be eligible if...** - You have had a prior cancer diagnosis - You have previously received radiation, chemotherapy, immunotherapy, or targeted therapy - Your life expectancy is less than 6 months Talk to your doctor to see if this trial is right for you.